Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  AVEO Pharmaceuticals, Inc.    AVEO

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

AVEO Pharmaceuticals, Inc. : DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders of AVEO Pharmaceuticals, Inc. of Upcoming Deadline

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/25/2013 | 11:25pm CEST

Rigrodsky & Long, P.A.:

  • Do you, or did you, own shares of AVEO Pharmaceuticals, Inc. (NASDAQ GS: AVEO)?
  • Did you purchase your shares before January 3, 2012, or between January 3, 2012 and May 1, 2013, inclusive?
  • Did you lose money in your investment in AVEO Pharmaceuticals, Inc.?
  • Do you want to discuss your rights?

Rigrodsky & Long, P.A., including former Special Assistant United States Attorney, Timothy J. MacFall, reminds shareholders of AVEO Pharmaceuticals, Inc. ("AVEO" or the "Company") (NASDAQ GS: AVEO) of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.

A complaint was filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities that purchased the common stock of AVEO between January 3, 2012 and May 1, 2013, inclusive (the "Class Period"), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the "Complaint"). If you wish to serve as lead plaintiff, you must move the Court no later than July 8, 2013.

If you purchased shares of AVEO during the Class Period, or purchased shares prior to the Class Period and still hold AVEO, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 825 East Gate Boulevard, Suite 300, Garden City, NY at (888) 969-4242, by e-mail to [email protected], or at: http://www.rigrodskylong.com/investigations/aveo-pharmaceuticals-inc-aveo.

A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

While Rigrodsky & Long, P.A. did not file the Complaint in this matter, the firm, with offices in Wilmington, Delaware and Garden City, New York, regularly litigates securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, including claims for breach of fiduciary duty and proxy violations in the Delaware Court of Chancery and in state and federal courts throughout the United States.

Attorney advertising. Prior results do not guarantee a similar outcome.

Rigrodsky & Long, P.A.
Timothy J. MacFall, Esquire
Peter Allocco
888-969-4242
516-683-3516
Fax: 302-654-7530
[email protected]
http://www.rigrodskylong.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AVEO PHARMACEUTICALS, INC.
04/21 TWO ABSTRACTS WE’RE WATCHING C : AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) ..
04/20 AVEO PHARMACEUTICALS : Announces Presentations at the 2017 ASCO Annual Meeting
04/13 AVEO PHARMACEUTICALS : Announces Closing of Public Offering and Full Exercise of..
04/13 AVEO PHARMACEUTICALS : Announces Submission of Response to Tivozanib Marketing A..
04/12 AVEO PHARMACEUTICALS, INC. (NASDAQ : AVEO) Files An 8-K Notice of Delisting or F..
04/06 AVEO PHARMACEUTICALS : Announces Pricing of $15.0 Million Public Offering of Com..
04/06 AVEO PHARMACEUTICALS : Announces Proposed Offering of Common Stock
04/05 AVEO PHARMACEUTICALS, INC. (NASDAQ : AVEO) Files An 8-K Regulation FD Disclosure
04/05 AVEO PHARMACEUTICALS INC : Regulation FD Disclosure, Financial Statements and Ex..
04/03 AVEO PHARMACEUTICALS : Announces Milestone Payment from CANbridge for AV-203
More news
Sector news : Bio Therapeutic Drugs
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
04/18DJACTELION : J&J Lifts Forecast on Actelion Tie-Up--Update
04/18DJJOHNSON & JOHNSON : Lifts Forecast on Actelion Tie-Up
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug -- Up..
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
04/17 Are We Hearing AVEO Pharmaceuticals' Death Rattle?
04/14 3 THINGS IN BIOTECH YOU SHOULD LEARN : April 14, 2017
04/13 EUSA Pharma submits responses to Day 180 questions related to tivozanib Europ..
04/12 AVEO transitions to Nasdaq Capital Market tomorrow
03/30 INSIDERINSIGHTS.COM DAILY ROUND UP 3 : Aveo, cbk, htgm, srg, dkl
Advertisement
Financials ($)
Sales 2017 4,32 M
EBIT 2017 -36,6 M
Net income 2017 -36,6 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 14,8x
Capi. / Sales 2018 5,73x
Capitalization 63,7 M
More Financials
Chart AVEO PHARMACEUTICALS, INC.
Duration : Period :
AVEO Pharmaceuticals, Inc. Technical Analysis Chart | AVEO | US0535881090 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 1,60 $
Spread / Average Target 166%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Michael P. Bailey President, Chief Executive Officer & Director
Keith S. Ehrlich CFO & Principal Accounting Officer
Michael N. Needle Chief Medical Officer
Emile Farhan Vice President-Technical Operations
Anthony B. Evnin Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AVEO PHARMACEUTICALS, ..11.48%64
AMGEN, INC.11.58%120 053
CELGENE CORPORATION6.39%95 807
GILEAD SCIENCES, INC.-7.49%86 604
REGENERON PHARMACEUTIC..0.83%39 455
ACTELION LTD26.98%30 323
More Results